ArticleBMC infectious diseases2026
Suppressive antibiotic therapy for spinal hardware infection: a retrospective cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpinal hardware infection (SHI) is one of the most devastating complications of spine surgery with challenging and undefined antibiotic treatment modalities.
methodsRetrospective cohort study of patients ≥ 18 years of age who underwent surgery for the treatment of SHI at a university center between 1st January2015, to 1st January 2020. The aim was to determine the appropriate duration of suppressive antibiotic therapy (SAT) for SHI based on recurrent infection rate on SAT, rate of adverse drug reaction (ADR) from SAT, and rate of antibiotic resistance to SAT in patients with SHI.
resultsThe median age of the 82 patients who met eligibility criteria for the study was 61 years (53-73), 55% were female, 60% had multimorbidity and 54% had early infection. Staphylococcus aureus was the most common cultured organism (45%) and 29 (35%) of patients had bacteremia. 54 (66%) received SAT with a median duration of 52 weeks (12 to 191 weeks). 12 (15%) had recurrence, while 8 (10%) developed recurrence on SAT. Neither SAT nor SAT duration (< 24 weeks, 24-52 or > 52 weeks) was associated with recurrence in early or late infection, regardless of hardware status. There was a non-significant higher recurrence rate with partial hardware revision, 7.3% (OR 6.30 [0.70-57.07]) and full hardware retention, 6.1% (OR 3.62 [0.39-33.30]) compared to complete hardware removal, (1.2%). ADR occurred in 6 (11%) of patients on SAT and in 11 (14%) of patents while on intravenous therapy, with no significant difference (mid-p exact 95% CI [0.32-1.80], p = 0.82). Only one case of drug resistance occurred with SAT.
conclusionIn patients who underwent surgery for SHI, neither the use of SAT nor SAT duration had any impact on recurrence of SHI regardless of SHI onset or hardware status. The rate of ADR with SAT was comparable to ADR with intravenous antibiotics and the rate of development of drug resistance was low. A randomized control trial is urgently needed to determine the role of SAT and its optimal application in the treatment of SHI. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.